Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021

Document Type

Article

Publication Date

10-22-2021

Publication Title

Morbidity and Mortality Weekly Report

Abstract

What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%). What are the implications for public health practice? This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years. Findings reinforce the importance of vaccination to protect U.S. youths against severe COVID-19.

First Page

1483

Last Page

1488

PubMed ID

34673751

Volume

70

Issue

42

Share

COinS